Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development declines year over year
Q3 FY2026 research & development of $110.6M fell 54.1% year over year, behind the -26.8% change in trailing-twelve-month research & development. Sequentially, it fell 46.7% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.
Context
- Research & development amounted to 18.3% of revenue in FY2025, down 3.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -54.1% toward the trailing-twelve-month pace of -26.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 782.74M USD
- Year-over-year change
- -11.5%
- 4-year CAGR
- +11.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 782.74M | -11.5% |
| FY2024 | 2024-12-31 | 884M | +4.0% |
| FY2023 | 2023-12-31 | 849.66M | +43.9% |
| FY2022 | 2022-12-31 | 590.45M | +16.7% |
| FY2021 | 2021-12-31 | 505.75M | — |
Research & Development vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's LTM Sep 2026 research & development of $623.61M is the 4th highest of the 9 companies compared; the peer median is $307.4M.
- Its year-over-year change of -26.8% is the 7th highest of 8, against a peer median of +9.1%.
- Research & development amounts to 13.2% of revenue for JAZZ, versus a peer median of 30.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.15B | +9.1% | +8.9% | 37.0% | |
| LTM Jun 2026 | $1.78B | — | -34.5% | 43.1% | |
| LTM Sep 2026 | $1.23B | +30.7% | +29.9% | 33.3% | |
| LTM Sep 2026 | $623.61M | -26.8% | +9.9% | 13.2% | |
| LTM Sep 2026 | $378.58M | -9.4% | +7.3% | 27.9% | |
| LTM Sep 2026 | $236.22M | +65.3% | +8.5% | 26.3% | |
| LTM Jun 2026 | $220.87M | +52.6% | +38.8% | 23.0% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Jun 2026 | $41.35M | -38.1% | +31.0% | 14.2% | |
| Peer median (excluding JAZZ) | $307.4M | +9.1% | +8.7% | 30.6% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B |
| Cost of Revenue | 440.76M | 540.52M | 435.58M | 445.71M | 503.3M |
| Gross Profit | 2.65B | 3.12B | 3.4B | 3.62B | 3.76B |
| Gross Margin | 85.8% | 85.2% | 88.6% | 89.0% | 88.2% |
| Research & Development | 505.75M | 590.45M | 849.66M | 884M | 782.74M |
| Selling, General & Admin | 1.45B | 1.42B | 1.34B | 1.39B | 1.81B |
| Operating Expenses | 2.48B | 3.18B | 2.82B | 2.91B | 3.54B |
| Depreciation & Amortization | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M |
| EBITDA | 1.03B | 1.47B | 1.45B | 1.52B | 262.76M |
| EBITDA Margin | 33.2% | 40.1% | 37.8% | 37.4% | 6.2% |
| Operating Income | 170.28M | (65.53M) | 578.58M | 716.63M | 224.42M |
| Operating Margin | 5.5% | -1.8% | 15.1% | 17.6% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 278.77M | 288.24M | 289.44M | 238.1M | 195.05M |
| Other Income / Expenses | (283.83M) | (317.18M) | (283.66M) | (247.94M) | (853.01M) |
| Income Before Tax | (113.55M) | (382.71M) | 294.92M | 468.69M | (628.59M) |
| Pre-Tax Margin | -3.7% | -10.5% | 7.7% | 11.5% | -14.7% |
| Income Tax Expense | 216.12M | (158.65M) | (119.91M) | (91.43M) | (272.44M) |
| Net Income | (328.95M) | (224.06M) | 414.83M | 560.12M | (356.15M) |
| Net Margin | -10.6% | -6.1% | 10.8% | 13.8% | -8.3% |
| EPS (Basic) | (5.51) | (3.58) | 6.55 | 9.06 | (5.84) |
| EPS (Diluted) | (5.51) | (3.58) | 6.10 | 8.65 | (5.84) |
| Weighted Avg Shares | 59.69M | 62.54M | 63.29M | 61.84M | 60.98M |
| Weighted Avg Shares (Diluted) | 59.69M | 62.54M | 72.07M | 66.01M | 60.98M |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.